brunistill - risultati della ricerca

viatris pharma gmbh - amlodipinum, valsartanum - compresse rivestite con film - amlodipinum 5 mg ut amlodipini besilas, valsartanum 80 mg, cellulosum microcristallinum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, Überzug: hypromellosum, macrogolum 8000, talcum, e 171, e 172 (flavum), vanillinum, pro compresso obducto. - essenziale ipertonia - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

amlodipin/valsartan vitatris 5 mg/160 mg compresse rivestite con film

viatris pharma gmbh - amlodipinum, valsartanum - compresse rivestite con film - amlodipinum 5 mg ut amlodipini besilas, valsartanum 160 mg, cellulosum microcristallinum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, e 172 (flavum), Überzug: hypromellosum, macrogolum 8000, talcum, e 171, e 172 (flavum), vanillinum, pro compresso obducto. - essenziale ipertonia - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

amlodipin/valsartan viatris 10 mg/160 mg compresse rivestite con film

viatris pharma gmbh - amlodipinum, valsartanum - compresse rivestite con film - amlodipinum 10 mg ut amlodipini besilas, valsartanum 160 mg, cellulosum microcristallinum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, Überzug: hypromellosum, macrogolum 8000, talcum, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), vanillinum, pro compresso obducto. - essenziale ipertonia - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

imatinib koanaa

koanaa healthcare gmbh - imatinib mesilato - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - agenti antineoplastici - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. i pazienti che hanno un basso o bassissimo rischio di recidiva non dovrebbero ricevere il trattamento adiuvante. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. tranne che nel recente diagnosi di lmc in fase cronica, non ci sono studi clinici controllati che dimostrano un beneficio clinico o un aumento della sopravvivenza per queste malattie.